NasdaqGS:SANABiotechs
Sana Biotechnology (SANA) Is Up 6.3% After Mayo-Backed SC451 Diabetes Cell Therapy Collaboration - What's Changed
Sana Biotechnology and Mayo Clinic recently announced a collaboration to advance SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes, with Mayo contributing clinical expertise and making an initial US$25,000,000 equity investment plus an option for additional funding.
The partnership aims to create standardized, scalable protocols for handling, delivering, and monitoring SC451 across diverse care settings, potentially strengthening both organizations’ roles in...